Bowen Hanes & Co’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.01M | Hold |
35,984
| – | – | 0.02% | 108 |
|
|
2026
Q1 | $1.01M | Hold |
35,984
| – | – | 0.02% | 108 |
|
|
2025
Q4 | $896K | Sell |
35,984
-8,400
| -19% | -$212K | 0.02% | 115 |
|
|
2025
Q3 | $1.13M | Sell |
44,384
-1,800
| -4% | -$44.4K | 0.03% | 107 |
|
|
2025
Q2 | $1.12M | Hold |
46,184
| – | – | 0.03% | 104 |
|
|
2025
Q1 | $1.17M | Hold |
46,184
| – | – | 0.03% | 108 |
|
|
2024
Q4 | $1.23M | Sell |
46,184
-15,287
| -25% | -$415K | 0.03% | 108 |
|
|
2024
Q3 | $1.78M | Sell |
61,471
-3,000
| -5% | -$87.5K | 0.05% | 99 |
|
|
2024
Q2 | $1.8M | Sell |
64,471
-275
| -0.4% | -$7.57K | 0.05% | 97 |
|
|
2024
Q1 | $1.8M | Hold |
64,746
| – | – | 0.05% | 100 |
|
|
2023
Q4 | $1.86M | Sell |
64,746
-6,383
| -9% | -$193K | 0.06% | 90 |
|
|
2023
Q3 | $2.36M | Buy |
71,129
+4,800
| +7% | +$170K | 0.08% | 84 |
|
|
2023
Q2 | $2.43M | Buy |
66,329
+150
| +0.2% | +$5.84K | 0.08% | 84 |
|
|
2023
Q1 | $2.7M | Sell |
66,179
-325
| -0.5% | -$14K | 0.09% | 80 |
|
|
2022
Q4 | $3.41M | Buy |
66,504
+9,205
| +16% | +$441K | 0.12% | 77 |
|
|
2022
Q3 | $2.51M | Sell |
57,299
-26,856
| -32% | -$1.3M | 0.1% | 83 |
|
|
2022
Q2 | $4.41M | Buy |
84,155
+750
| +0.9% | +$38.2K | 0.16% | 76 |
|
|
2022
Q1 | $4.32M | Sell |
83,405
-2,550
| -3% | -$132K | 0.13% | 89 |
|
|
2021
Q4 | $5.08M | Sell |
85,955
-4,097
| -5% | -$203K | 0.14% | 86 |
|
|
2021
Q3 | $3.87M | Sell |
90,052
-70
| -0.1% | -$3.1K | 0.12% | 85 |
|
|
2021
Q2 | $3.53M | Hold |
90,122
| – | – | 0.11% | 83 |
|
|
2021
Q1 | $3.27M | Hold |
90,122
| – | – | 0.1% | 81 |
|
|
2020
Q4 | $3.32M | Buy |
90,122
+2,833
| +3% | +$104K | 0.11% | 78 |
|
|
2020
Q3 | $3.04M | Buy |
87,289
+1,813
| +2% | +$63.6K | 0.11% | 77 |
|
|
2020
Q2 | $2.65M | Buy |
85,476
+11,641
| +16% | +$395K | 0.11% | 76 |
|
|
2020
Q1 | $2.29M | Hold |
73,835
| – | – | 0.11% | 74 |
|
|
2019
Q4 | $2.75M | Hold |
73,835
| – | – | 0.11% | 81 |
|
|
2019
Q3 | $2.52M | Hold |
73,835
| – | – | 0.11% | 81 |
|
|
2019
Q2 | $3.04M | Sell |
73,835
-6,166
| -8% | -$245K | 0.13% | 73 |
|
|
2019
Q1 | $3.22M | Sell |
80,001
-16,171
| -17% | -$648K | 0.14% | 72 |
|
|
2018
Q4 | $3.98M | Buy |
96,172
+20,447
| +27% | +$849K | 0.2% | 69 |
|
|
2018
Q3 | $3.17M | Sell |
75,725
-843
| -1% | -$32.5K | 0.14% | 77 |
|
|
2018
Q2 | $2.64M | Sell |
76,568
-1,554
| -2% | -$53.1K | 0.12% | 82 |
|
|
2018
Q1 | $2.63M | Hold |
78,122
| – | – | 0.12% | 83 |
|
|
2017
Q4 | $2.69M | Hold |
78,122
| – | – | 0.12% | 87 |
|
|
2017
Q3 | $2.65M | Hold |
78,122
| – | – | 0.12% | 88 |
|
|
2017
Q2 | $2.49M | Sell |
78,122
-738
| -0.9% | -$23.3K | 0.12% | 87 |
|
|
2017
Q1 | $2.56M | Sell |
78,860
-564
| -0.7% | -$17.8K | 0.13% | 85 |
|
|
2016
Q4 | $2.45M | Sell |
79,424
-6,725
| -8% | -$205K | 0.13% | 85 |
|
|
2016
Q3 | $2.77M | Buy |
86,149
+7,484
| +10% | +$250K | 0.15% | 82 |
|
|
2016
Q2 | $2.63M | Buy |
78,665
+1,607
| +2% | +$51.3K | 0.14% | 82 |
|
|
2016
Q1 | $2.17M | Sell |
77,058
-8,432
| -10% | -$241K | 0.12% | 80 |
|
|
2015
Q4 | $2.62M | Sell |
85,490
-395
| -0.5% | -$12.4K | 0.15% | 84 |
|
|
2015
Q3 | $2.56M | Buy |
85,885
+522
| +0.6% | +$16.7K | 0.15% | 90 |
|
|
2015
Q2 | $2.72M | Buy |
85,363
+3,446
| +4% | +$112K | 0.14% | 95 |
|
|
2015
Q1 | $2.7M | Buy |
81,917
+562
| +0.7% | +$17.9K | 0.13% | 91 |
|
|
2014
Q4 | $2.4M | Buy |
81,355
+2,367
| +3% | +$67.9K | 0.12% | 92 |
|
|
2014
Q3 | $2.22M | Buy |
78,988
+5,302
| +7% | +$149K | 0.11% | 104 |
|
|
2014
Q2 | $2.08M | Buy |
73,686
+1,404
| +2% | +$40K | 0.1% | 102 |
|
|
2014
Q1 | $2.2M | Buy |
72,282
+2,108
| +3% | +$62.9K | 0.11% | 99 |
|
|
2013
Q4 | $2.04M | Sell |
70,174
-17,724
| -20% | -$516K | 0.1% | 97 |
|
|
2013
Q3 | $2.4M | Buy |
87,898
+263
| +0.3% | +$7.16K | 0.12% | 93 |
|
|
2013
Q2 | $2.33M | Buy |
+87,635
| New | +$2.42M | 0.12% | 93 |
|
Other funds holding PFE
Bowen Hanes & Co's PFE Position: Q2 2026 in Review
Bowen Hanes & Co held its Pfizer (PFE) position steady in Q2 2026 at 35,984 shares worth $1.01M. The position accounts for 0.02% of the portfolio, ranked #108.
Bowen Hanes & Co first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.08M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Bowen Hanes & Co held 35,984 shares of Pfizer worth $1.01M as of Q2 2026.
- Bowen Hanes & Co left its Pfizer share count unchanged in Q2 2026.
- Pfizer made up 0.02% of Bowen Hanes & Co's portfolio in Q2 2026, its #108 holding.
- Bowen Hanes & Co first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
- Bowen Hanes & Co's Pfizer position peaked at $5.08M in Q4 2021.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Bowen Hanes & Co's 13F filing for Q2 2026, filed 13 Aug 2026.